CXCR4 and neuroendocrine neoplasm: Previous studies have already provided evidence that CXCR4 emerges as a suitable target for imaging and therapy in multiple solid tumors, including ACC, ovarian cancer, neuroendocrine tumors, or SCLC [9, 30–32].